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Abstract
Serum C-reactive protein (CRP) is a sensitive marker of systemic inflammation. Since there is a 
well-recognized relationship between local inflammation and colorectal cancer, we aimed to 
evaluate whether serum CRP levels were associated with the occurrence of colorectal adenomas 
and serrated polyps using data from a large adenoma prevention trial. 930 participants with a 
history of colorectal adenomas were enrolled in a randomized trial of calcium supplementation 
(1200 mg/day) for the prevention of colorectal adenomas. Outcomes in this analysis are 
metachronous adenomas (and advanced neoplasms specifically), and serrated polyps at follow-up 
colonoscopy. High sensitivity CRP levels were measured 1 year following baseline colonoscopy. 
Multivariate analysis was performed to estimate risk ratios (RR) using Poisson regression, 
controlling for potential confounders. We measured serum CRP levels in 689 participants(mean 
CRP 3.62mg/L ± 5.72). There was no difference in CRP levels with respect to calcium vs. placebo 
treatment assignment (p=0.99). After adjustment for potential confounders, we found no 
association between CRP level and risk of recurrent adenoma or advanced lesion (Quartile 4 vs. 
Quartile 1: RR (95% CI) = 0.99 (0.73, 1.34) and 0.92 (0.49, 1.75) respectively). Similarly, no 
association was seen between CRP levels and riskof serrated polypsor proximal serrated 
polyps(Quartile 4 vs. Quartile 1: RR (95% CI) = 1.32 (0.85, 2.03) and 1.19 (0.54, 2.58) 
respectively. In conclusion, this large prospective colorectal adenoma chemoprevention study 
found no significant relationship between CRP levels and occurrence of adenomas, advanced 
neoplasms, or serrated polyps.
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Introduction
Inflammation is associated with colorectal carcinogenesis(1). Serum C-reactive protein 
(CRP) is a sensitive yet nonspecific marker of systemic inflammation that is elevated in 
association with chronic inflammatory conditions(2),coronary heart disease (3), obesity (4), 
and various cancers (5).Several case-control studies have reported elevated circulating CRP 
concentrations in CRC patients compared to healthy controls (6, 7). Additionally, a recent 
systematic review of prospective studies reported an increased risk of CRC associated with 
CRP elevation(8).
However, published data are less conclusive regarding the association between serum CRP 
and colorectal adenomas. While some studies have reported that CRP is associated with 
higher risk of colorectal adenomas (9, 10), others have found null (11-13), or even inverse 
associations(14). To our knowledge, no study has previously examined the association 
between inflammatory markers and serrated polyps (SPs), yet some of these lesions are now 
understood to be important CRC precursors as well.
A correlation of serum CRP levels with colonoscopic findings would suggest an important 
role of inflammation in the early phases of colorectal carcinogenesis. CRP could be a useful 
clinical biomarker for risk stratification and/or screening test selection. In this context, we 
aimed to investigate whether CRP elevation is associated with an increased risk of adenoma 
or SPoccurrence using data from a large polyp chemoprevention trial.
Materials and Methods
Study design and participants
The details of the study design have beenpublished elsewhere(15). Briefly,the Calcium 
Polyp Prevention Study was conducted at 6 centers across the US between November 1988 
and December 1996. Subjects were recruited for participation if they had an index 
colonoscopy with at least 1 large-bowel adenoma within 3 months (and no remaining polyps 
in the large bowel), were >21 to <80 years old, in good health, and without a history of 
familial polyposis or invasive large-bowel cancer. Baseline data collection included 
demographics (age, gender, race), smoking status, and measurement of height and weight. 
Body mass index (BMI) was calculated as[weight (kg)]/[height (m)]2and obesity was 
defined as a BMI ≥30 kg/m2. 930 subjects underwent randomization to calcium carbonate (3 
g daily; 1.2 g elemental calcium) or placebo in blinded fashion. Participants underwent 
follow-up colonoscopies at approximately one and four years after the baseline examination 
to determine occurrence of colorectal polyps (Figure 1). All participants provided written 
informed consent and this study was approved by the Institutional Review Boards at all 
study sites.
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At enrollment and around the time of each of the two follow-up colonoscopies, we obtained 
specimens of venous blood. Serum was initially stored at -20°C or below, pending shipment 
to the central laboratory (Dartmouth) for storage at -70°C until analysis. High sensitivity 
CRP measurements were performed on blood samples obtained at the year 1 follow up visit. 
At the time of blood collection, participants had been taking the study drug for 
approximately 9 months. Serum CRP was measured using CRPHS Tina-quant testing kits on 
a Roche/Hitachi modular P analyzer with a limit of detection: 0.03 mg/L (0.00003 g/L).
Outcome measurement
For this study, only participants who had colonoscopies at year 4 were included and the risk 
period was the time between years 1 and 4 following baseline colonoscopy. At each 
colonoscopy, the endoscopist recorded the size and location of all mucosal lesions. All 
polyps seen after randomization were removed and examined histologically by the study 
pathologist. Advanced neoplasms were defined as lesions with >25% villous histology, size 
≥1 cm or high-grade dysplasia/cancer.Although current understanding is that SPscan be 
categorized as hyperplastic polyps (HP), sessile serrated adenomas (SSA) and traditional 
serrated adenomas (TSA)(16), at the time this study was done, essentially all serrated lesions 
were interpreted as HPs. Proximal (or right-sided)SPs were defined as polyps occurring in 
the cecum, ascending and transverse colon. We also performed a secondary cross-sectional 
analysis of year 1 colonoscopy results.
Statistical analysis
CRP was analyzed as a categorical variable (dichotomous, split at the median, and into 
quartiles). Bivariate comparisons were performed using Student’s t-tests or Chi-squared 
tests. Generalized linear models were performed using a Poisson distribution to estimate risk 
ratios (RR) and 95% confidence intervals (CI)adjusted for age, sex, center, baseline 
adenoma history, treatment arm, and surveillance colonoscopy interval. Quartile 1 (Q1) and 
median or below CRP levels were the referent groups used in modeling. Statistical analyses 
were performed using STATA (College Station, TX, USA) and SAS (Cary, NC, USA).
Results
Participant characteristics
Baseline characteristics of participants are presented in Table 1. A total of 832 participants 
underwent a year 4 follow up colonoscopy;689 (83%) of these had CRP data and could be 
included in this analysis. There was no difference between the study treatment groups and 
those excluded for lack of CRP data with respect to age, gender, BMI, or smoking status 
(data not shown).
Serum CRP levels
The mean and median CRP serum levels among all participants were 3.62 and 1.79mg/L 
respectively (Standard deviation 5.72; interquartile range 0.75, 3.94). For reference, CRP 
levels >10mg/L suggest active infection or inflammation, so most participants in this study 
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had low levels.Age, female sex, African American race, obesity, and smoking were 
associated with higher mean CRP levels (Table 1). CRP levels did not differ significantly 
based on baseline adenoma or SP status. There was no difference in CRP level(log-
transformed) with respect to randomization to calcium vs. placebo treatment (p=0.99).
Serum CRP andadenoma recurrence
The RR for adenomas andadvanced neoplasms did not vary with CRP levels in crude 
analyses. After adjustment for age, sex, treatment group, study center, colonoscopy interval, 
and adenoma history, there was also no statistically significant association between CRP 
level and risk of metachronous adenomas(Q4 vs. Q1: RR = 0.99 (95% CI 0.73, 1.34)), or 
advanced neoplasms (Q4 vs. Q1: RR = 0.92 (95% CI 0.49, 1.75))(Table 2). Analysis of 
dichotomized CRP levels revealed similar results. There was also no association between 
CRP levels and adenomas found on the year 1 colonoscopy (Supplementary table 1). Risk 
for advanced neoplasms at the year 1 exam did appear to be increased among subjects whose 
CRP was in the highest quartile, though this estimate was imprecise with wide confidence 
intervals. In all analyses,additional adjustment for BMI did not materially affect RR’s found 
(data not shown).
Serum CRP and occurrence of serrated polyps
Higher CRP levels were also not associated with increased risk of SPs in crude analyses. 
Multivariable analysis also did not demonstrate an association between CRP level and risk 
of any SP(Q4 vs. Q1: RR = 1.32 (95% CI 0.85, 2.03)) or right-sided SP (Q4 vs. Q1: RR = 
1.19 (95% CI 0.54, 2.58)) occurrence during follow-up (Table 2). CRP levels greater than 
the median were also not associated with occurrence of any SPor proximal SPs 
specifically.There was also no association between CRP levels and SPs found on the year 1 
colonoscopy (Supplementary table 1).
Discussion
In this large multi-center prospective study, we found that CRP levels were not associated 
with an increased risk of recurrence of conventional adenomas. We also did not find any 
association between CRP levels and occurrence of SPs during follow up. In addition, we 
found no effect of calcium supplementation on CRP levels, similar to other studies(17, 18).
CRP is an acute-phase protein that is synthesized in the liver in response to proinflammatory 
cytokine signaling, primarily via interleukin-6 and tumor necrosis factor alpha. (19). An 
important role of CRP is to bind phosphocholine on pathogens as well as apoptotic or 
necrotic host cells, which in turn activates the complement system and recruits 
phagocytes(19).Serum CRP rises rapidly in response to tissue injury or infection, but CRP 
elevation (generally at low levels) is also seen in chronic inflammatory or neoplastic states, a 
process that is likely mediated by different signaling mechanisms(20).
Whether CRP levels are associated with the development of adenomas and SPsis an 
important question, since these are the chief knownprecursor lesions of sporadic CRC. If 
elevated serum CRP levels predict polyp risk, this could have important implications for 
CRC screening and prevention. However, the existing literature on this topic is inconsistent. 
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A recent Japanese study reported that CRP levels> 90th percentile were associated with a 
>2-fold increase in the odds of large colorectal adenomas(9). A cross-sectional Chinese 
study also reported that elevated CRP levels were associated with increased risk of advanced 
adenomas and multiple adenomas(10). However, several studies have reported no significant 
association between CRP and adenomas(11-13).Interestingly, one study suggested that CRP 
levels may be inversely associated with risk of colorectal neoplasia; using data from the 
Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial, Gunter et al. 
reported that participants with the highest CRP levels had the lowest risk of incident 
colorectal adenoma (Q4 vs. Q1: OR 0.65 (95% CI 0.41, 1.03, p for trend = 0.03)(14).
A possible explanation for discordant risk of colorectal adenomas seen in different studies 
may be related to differences in CRP metabolism among different subjects. A number of 
studies have demonstrated that CRP levels vary based on genetic variations in the CRP gene 
(21, 22).A few studies have investigated CRP gene polymorphisms and risk of colorectal 
neoplasia. Ognjanovic et al. reported that certain single nucleotide polymorphisms (SNP) in 
the CRP gene (rs1205C and rs1130864A) were associated with both higher CRP levels and 
a decreased adenoma risk(13).In contrast, Poole et al. also reporteddifferent CRP 
polymorphisms that were associated with increased risk of both adenomas and hyperplastic 
polyps(23).CRP gene polymorphisms have also been associated with the risk of CRC, and 
specificallyCPG-island methylator phenotype (CIMP) cancers (24).Given these findings, it 
is possible that heterogeneity of CRP alleleswithin the study population and the associated 
differences in CRP elevations and corresponding risk of polyps could explain our and other 
reported null associations between CRP levels and CRC precursors.
We are not aware of any other studies that have examined the relationship between CRP 
serum levels and SPs. Because a keymechanism of SP development is thought to be 
inhibition of apoptosis(25) and CRP plays a role in apoptosis, this relationship could shed 
light on the molecular pathology of the serrated pathway. In this study, we found no 
substantial relationship between CRP levels and occurrence of SPs or right-sided SPs in 
particular. Nevertheless, it is possible that CRP might be associated with more advanced SPs 
such as SSAs or TSAs. Additionally, relatively small numbers of SPs limited our ability to 
detect a statisticallysignificant association.
This was a large, prospective study of participants with a history of colorectal adenomas. 
CRP measurements were obtained in standardized fashion from serum collected at 1 year 
after their baseline colonoscopy, which we believed to be an optimal time to measure a 
potential biomarker of colonic neoplasia. All pathology from follow up colonoscopies was 
centrallyreviewed, to optimize the fidelity of outcome measurements (i.e. adenoma and SP 
occurrence). Furthermore, we used a high-sensitivity CRP assay because it measures very 
low levels of CRP, an important consideration in our cohort of relatively healthy 
colonoscopy screenees. However, CRP may only be associated with risk of adenoma 
recurrence at very high levels, and thus the distribution of our data (most subjects had very 
low CRP measurements) could obscure this relationship. We considered the possibility that 
obesity confounded the association between CRP and polyp occurrence. However, when we 
adjusted for BMI, our estimates did not change substantially.It is possible that change or rise 
in CRP levels may correlate with polyp occurrence, but we were unable to determine this 
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based on our data. Finally not all participants in the parent trial provided CRP samples, 
which could introduce selection bias, though the non-participation rate was relatively small, 
and those with missing CRP data were similar with respect to age, gender, race, BMI and 
smoking status compared to those included in this analysis.
In summary, in this large prospective study, we found no significant relationship between 
CRP levels and occurrence of adenomasor serrated polyps. It is possible however, that CRP 
is a more useful marker of colorectal neoplasia during latter stages of carcinogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study schematic showing timing of C-reactive protein measurement and study 
colonoscopies
*689/930 subjects had both a year 4 colonoscopy and a CRP measurement and were 
included in the study. Reasons for missing CRP data included refusal of blood draw or blood 
sample not obtained (n=17), unevaluable specimen or lab error (n=11), and unavailable or 
missing samples (n=115).hsCRP: high sensitivity C-reactive protein
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Table 1
Circulating serum high sensitivity C-reactive protein level by baseline subject characteristics
Baseline characteristic n Serum CRP mean (SD) p value
Age 0.01
<50 96 1.20 (2.96)
 50-59 176 1.57 (3.32)
 60-69 316 1.85 (3.80)
≥70 101 2.10 (3.37)
Gender 0.01
 Male 496 1.58 (3.52)
 Female 193 2.07 (3.46)
Race/Ethnicity <0.0001
 White 588 1.69 (3.40)
 Black 48 3.14 (3.63)
 Hispanic 23 1.80 (2.78)
 Other 30 0.66 (4.54)
BMI <0.0001
<25 212 1.21 (3.57)
 25-29 309 1.62 (3.31)
 30+ 166 2.86 (3.33)
Smoking Status 0.03
 Never 230 1.48 (3.47)
 Former 337 1.72 (3.56)
 Current 122 2.15 (3.43)
Study treatment 0.99
 Placebo 349 1.70 (3.62)
 Calcium 340 1.70 (3.43)
Number of baseline adenomas 0.30
 1 380 1.77 (3.54)
 2 155 1.48 (3.56)
 3 or more 154 1.77 (3.45)
Advanced adenoma at baseline 0.95
 No 442 1.70 (3.46)
 Yes 247 1.71 (3.64)
Hyperplastic polyp at baseline 0.20
 No 510 1.64 (3.48)
 Yes 179 1.89 (3.63)
p values reflect differences in log-transformed CRP between categories, and were obtained using Student’s t-tests
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2 subjects had unknown BMI
BMI: body mass index; SD: Standard deviation; CRP: C-reactive protein.
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Table 2
Risk ofconventional adenomas and serratedpolypsduring follow-up (years 2-4) associated with categories of 
circulating serum high sensitivity C-reactive protein levels.
CRP levels # events/N (%) Crude RR (95% CI) Adjusted* RR (95% CI)
All Adenomas
Dichotomous
 ≤median 121/337 (35.9%) 1.00 (REF) 1.00(REF)
>median 126/335 (37.6%) 1.05 (0.86, 1.28) 0.99 (0.80, 1.21)
Quartiles
Q1: ≤0.74mg/L 55/164 (33.5%) 1.00 (REF) 1.00 (REF)
Q2: 0.74-1.785mg/L 66/173 (38.2%) 1.14 (0.86, 1.51) 1.11 (0.83, 1.49)
Q3: 1.785-3.90mg/L 66/169 (39.1%) 1.16 (0.88, 1.55) 1.09 (0.82, 1.46)
Q4: >3.90mg/L 60/166 (36.1%) 1.08 (0.80, 1.44) 0.99 (0.73, 1.34)
Advanced Neoplasms†
Dichotomous
 ≤median 30/330 (9.1%) 1.00 (REF) 1.00 (REF)
>median 36/325 (11.1%) 1.22 (0.77, 1.93) 0.98 (0.62, 1.55)
Quartiles
 Q1: ≤0.74mg/L 16/162 (9.9%) 1.00 (REF) 1.00 (REF)
 Q2: 0.74-1.785mg/L 14/168 (8.3%) 0.84 (0.43, 1.67) 0.85 (0.43, 1.67)
 Q3: 1.785-3.90mg/L 17/164 (10.4%) 1.05 (0.55, 2.01) 0.89 (0.47, 1.70)
 Q4: >3.90mg/L 19/161 (11.8%) 1.19 (0.63, 2.25) 0.92 (0.49, 1.75)
Serrated Polyps
Dichotomous
 ≤median 69/343 (20.1%) 1.00 (REF) 1.00 (REF)
>median 75/346 (21.7%) 1.08 (0.81, 1.44) 1.10 (0.81, 1.48)
Quartiles
 Q1: ≤0.74mg/L 32/167 (19.2%) 1.00 (REF) 1.00 (REF)
 Q2: 0.74-1.785mg/L 37/176 (21.0%) 1.10 (0.72, 1.67) 1.19 (0.77, 1.84)
 Q3: 1.785-3.90mg/L 35/173 (20.2%) 1.06 (0.69, 1.62) 1.10 (0.71, 1.71)
 Q4: >3.90mg/L 40/173 (23.1%) 1.21 (0.80, 1.83) 1.32 (0.85, 2.03)
Proximal Serrated Polyps
Dichotomous
 ≤median 24/343 (7.0%) 1.00 (REF) 1.00 (REF)
>median 23/346 (6.7%) 0.95 (0.55, 1.65) 1.00 (0.59, 1.71)
Quartiles
 Q1: ≤0.74mg/L 11/167 (6.6%) 1.00 (REF) 1.00 (REF)
 Q2: 0.74-1.785mg/L 13/176 (7.4%) 1.12 (0.52, 2.44) 1.17 (0.55, 2.48)
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CRP levels # events/N (%) Crude RR (95% CI) Adjusted* RR (95% CI)
 Q3: 1.785-3.90mg/L 11/173 (6.4%) 0.97 (0.43, 2.17) 1.01 (0.46, 2.22)
 Q4: >3.90mg/L 12/173 (6.9%) 1.05 (0.48, 2.33) 1.19 (0.54, 2.58)
CRP: C-reactive protein; RR: risk ratio; CI: confidence interval; Q: quartile
*
Adjusted for treatment arm, age, sex, center, baseline adenoma history, and surveillance colonoscopy interval; RRs obtained by GLM with 
Poisson distribution.
†
Advanced neoplasm defined as an adenoma ≥10mm, and/or with villous histology, or high grade dysplasia/cancer
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